12:00 AM
 | 
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Revolade eltrombopag regulatory update

The U.K.'s NICE issued an updated preliminary appraisal recommending the use of Revolade eltrombopag from GlaxoSmithKline to treat chronic idiopathic thrombocytopenia purpura (ITP) in adults who have had a splenectomy and whose condition is refractory to other treatments or as a second-line treatment in adults who have not had a...

Read the full 230 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >